{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04906213",
            "orgStudyIdInfo": {
                "id": "Pro00107752"
            },
            "organization": {
                "fullName": "Duke University",
                "class": "OTHER"
            },
            "briefTitle": "CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients",
            "officialTitle": "CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients",
            "acronym": "CREST-KT",
            "therapeuticArea": [
                "Endocrinology",
                "Nephrology and Renal Diseases"
            ],
            "study": "cardiorenal-effects-of-inhibition-in-kidney-transplant-recipients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-18",
            "studyFirstSubmitQcDate": "2021-05-24",
            "studyFirstPostDateStruct": {
                "date": "2021-05-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Duke University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.",
            "detailedDescription": "A screening visit will occur at which time an informed consent will be obtained, and eligibility determined. Women of childbearing potential will have a serum pregnancy test performed. This will be followed by a baseline visit. A renal biopsy and a 3D echocardiogram will be performed. At the next visit randomization will be performed and the subjects will receive their study medication, either empagliflozin or a placebo. Following the randomization visit the subject will return every 3 months (visits 2-7) for a total of 6 visits spanning 18 months. At each visit vital signs and weight will be taken. Other procedures include labs drawn for hematology, basic chemistry, coagulation, Glycated hemoglobin and serum insulin. A 3 D echocardiogram is repeated on Visits 4 and 6. A renal biopsy is repeated on Visit 3."
        },
        "conditionsModule": {
            "conditions": [
                "Kidney Transplant; Complications",
                "Diabetes Mellitus, Type 2"
            ],
            "keywords": [
                "Post operative kidney transplant"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Placebo-controlled, double-blind, randomized clinical trial",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 72,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm I: With Type II Diabetes",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Kidney Transplant recipient with Type II diabetes, randomized to either Empagliflozin or a placebo.",
                    "interventionNames": [
                        "Drug: Empagliflozin10Mg Tab",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Arm 2: Without Diabetes",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Kidney Transplant recipient without Type II diabetes, randomized to either Empagliflozin or a placebo",
                    "interventionNames": [
                        "Drug: Empagliflozin10Mg Tab",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Empagliflozin10Mg Tab",
                    "description": "Empagliflozin10 Mg daily or placebo daily for 18 months",
                    "armGroupLabels": [
                        "Arm 2: Without Diabetes",
                        "Arm I: With Type II Diabetes"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "10Mg Placebo Tab",
                    "armGroupLabels": [
                        "Arm 2: Without Diabetes",
                        "Arm I: With Type II Diabetes"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in kidney function as measured by eGFR",
                    "description": "eGFR will be measured by blood test",
                    "timeFrame": "Baseline, 6 months, 9 months, 12 months and 18 months"
                },
                {
                    "measure": "Change in kidney function as measured by albuminuria",
                    "description": "Albuminuria will be measured by urine Albumin/Creatinine Ratio",
                    "timeFrame": "Baseline, 6 months, 9 months, 12 months and 18 months"
                },
                {
                    "measure": "Change in cardiac structure",
                    "description": "Cardiac structure as measured by the 3D echocardiogram",
                    "timeFrame": "Baseline, month 9 and month15"
                },
                {
                    "measure": "Change in blood insulin level",
                    "description": "Blood insulin level will be determined lab values",
                    "timeFrame": "Baseline, month 6 and month 18"
                },
                {
                    "measure": "Change in fasting blood sugar",
                    "description": "Fasting Blood sugar will be determined lab values",
                    "timeFrame": "Baseline, month 6 and month 18"
                },
                {
                    "measure": "Number of Urinary Tract infections",
                    "description": "Data to be gathered from chart review and patient report",
                    "timeFrame": "up to 18 months"
                },
                {
                    "measure": "Number of Genital infections",
                    "description": "Data to be gathered from chart review and patient report",
                    "timeFrame": "up to 18 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in kidney biopsy as measured by percentage of interstitial fibrosis",
                    "timeFrame": "Baseline and 6 months"
                },
                {
                    "measure": "Changes in Hemoglobin A1C as measured by blood work",
                    "timeFrame": "Baseline, Months 3,6,9,12,15 and 18"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Adverse events will be collected form the medical record and patient report",
                    "timeFrame": "up to 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Equal to or greater than 12 months and up tp 60 months post kidney transplant\n2. Estimated glomerular filtration rate (eGFR) equal to or greater than 30ml/min/1.73m squared at screening\n3. Standard immunosuppression, including calcineurin inhibitor, Mycophenolate Mofetil or Sodium and a glucocorticoid\n4. Able to provide written consent -\n\nExclusion Criteria:\n\n1. Type I diabetes\n2. Any other solid organ transplant\n3. Hemoglobin A1c greater than 12 %\n4. SGLT2i use at the time of enrollment\n5. Prior SGLT2i allergy or intolerance\n6. Pregnant or nursing at the time of enrollment\n7. History of antibody medicated rejection (AMR) or a Banff score greater than 2B for acute cellular rejection (ACR)\n8. Active anticoagulant use other than aspirin 81 mg for primary prevention of cardiovascular disease\n9. Known positive donor-specific antibodies prior to enrollment\n10. Uncircumcised men\n11. Greater than 2 urinary tract infections (UTI) over the 12 months prior to enrollment\n12. Any genital infections over the 12 months prior to enrollment -",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rachael Abuin, BSN",
                    "role": "CONTACT",
                    "phone": "919-684 8136",
                    "email": "rachael.abuin@duke.edu"
                },
                {
                    "name": "Daniel Edmonston, MD",
                    "role": "CONTACT",
                    "phone": "919-668-4596",
                    "email": "daniel.edmonston@duke.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Myles Wolf, MD",
                    "affiliation": "Duke University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Duke University Medical Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rachael Abuin, BSN",
                            "role": "CONTACT",
                            "phone": "919-684-8136",
                            "email": "rachael.abuin@duke.edu"
                        },
                        {
                            "name": "Daniel Edmonston, MD",
                            "role": "CONTACT",
                            "phone": "919 668 4596",
                            "email": "Daniel.edmonston@duke.edu"
                        },
                        {
                            "name": "Myles Wolf, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "25081992",
                    "type": "RESULT",
                    "citation": "Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015 Jan;28(1):10-21. doi: 10.1111/tri.12413. Epub 2014 Aug 20."
                },
                {
                    "pmid": "26981940",
                    "type": "RESULT",
                    "citation": "Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827. No abstract available."
                },
                {
                    "pmid": "28605608",
                    "type": "RESULT",
                    "citation": "Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12."
                },
                {
                    "pmid": "30415602",
                    "type": "RESULT",
                    "citation": "Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10."
                },
                {
                    "pmid": "30862658",
                    "type": "RESULT",
                    "citation": "Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Asberg A, Jenssen T. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care. 2019 Jun;42(6):1067-1074. doi: 10.2337/dc19-0093. Epub 2019 Mar 12."
                },
                {
                    "pmid": "27470878",
                    "type": "RESULT",
                    "citation": "Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Individual data will not be shared"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003924",
                    "term": "Diabetes Mellitus, Type 2"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "asFound": "Diabetes Mellitus, Type 2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000570240",
                    "term": "Empagliflozin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000077203",
                    "term": "Sodium-Glucose Transporter 2 Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M258082",
                    "name": "Empagliflozin",
                    "asFound": "Continued",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}